1. Plasma transfusion-transmission of Zika virus in mice and macaques.
- Author
-
Van Rompay, Koen, Coffey, Lark, Yee, JoAnn, Singapuri, Anil, Stuart, Jackson, Lanteri, Marion, Santa Maria, Felicia, Lu, Kai, Singh, Inderdeep, Bakkour, Sonia, Stone, Mars, Williamson, Phillip, Muench, Marcus, Busch, Michael, and Simmons, Graham
- Subjects
Infectious disease testing ,pathogen reduction ,transfusion-transmitted disease ,Animals ,Female ,Humans ,Mice ,Pregnancy ,Blood Component Transfusion ,Blood Transfusion ,Plasma ,RNA ,Viral ,Zika Virus ,Zika Virus Infection - Abstract
BACKGROUND: Zika virus (ZIKV) epidemics with infections in pregnant women are associated with severe neurological disease in newborns. Although an arbovirus, ZIKV is also blood transfusion-transmitted (TT). Greater knowledge of the efficiency of ZIKV TT would aid decisions on testing and pathogen reduction technologies (PRT). STUDY DESIGN AND METHODS: Plasma units from ZIKV RNA-reactive blood donors were used to study infectivity in vitro, in mice, and in macaques. Furthermore, plasma units were subjected to PRT using amotosalen/ultraviolet light A (A/UVA) before transfusion. RESULTS: In vitro infectivity of ZIKV RNA-reactive plasma varied between 100 and 1000 international units (IU) of ZIKV RNA. Immunodeficient mice were more sensitive with as low as 32 IU sufficient to infect 50% of mice. 50-5500 IU of RNA led to TT in macaques using dose escalation of three different RNA-positive, seronegative plasma units. In contrast, RNA-reactive units collected postseroconversion were not infectious in macaques, even at a dose of 9 million IU RNA. After A/UVA PRT, transfusion of plasma containing up to 18 million IU was no longer infectious in vitro and did not result in ZIKV TT in macaques. CONCLUSION: Significant risks of ZIKV TT are likely confined to a relatively short viremic window before seroconversion, and that sensitive nucleic acid amplification testing likely identifies the majority of infectious plasma. PRT was demonstrated to be effective at preventing ZIKV TT. Considering that there is no approved ZIKV vaccine, these data are relevant to mitigate the risk of TT during the future ZIKV outbreaks.
- Published
- 2023